"Toremifene" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.
| Descriptor ID |
D017312
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Toremifene".
Below are MeSH descriptors whose meaning is more specific than "Toremifene".
This graph shows the total number of publications written about "Toremifene" by people in this website by year, and whether "Toremifene" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Toremifene" by people in Profiles.
-
Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated? J Clin Oncol. 2013 Feb 10; 31(5):515-6.
-
Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007 Sep; 178(3 Pt 2):S9-S13.
-
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
-
Induction of atypical ductal hyperplasia in mouse mammary gland organ culture. J Natl Cancer Inst. 2001 Jul 18; 93(14):1103-6.
-
Differences in toxicity findings for antiestrogens. J Clin Oncol. 1998 May; 16(5):1999-2000.
-
Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol. 1998 Jan; 16(1):348-53.
-
Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 1997 Apr 15; 57(8):1438-41.
-
High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Res Treat. 1995; 36(1):35-40.